Navigation Links
GlaxoSmithKline Opens $600million Vaccine Plant In Singapore

New state-of-the-art vaccine plant to hire 200 staff in Singapore, GSK and the Singapore Economic Development Board (EDB) set up endowment fund.

Singapore (PRWEB) June 16, 2009 -- Singapore's pharmaceutical industry has moved into higher gear, with the opening of a state-of-the-art vaccine plant. The new plant is GlaxoSmithKline's (GSK) first primary vaccine manufacturing facility and its biggest investment in Asia. The plant, which involves a total investment of S$600 million, underscores GSK's strong commitment to Singapore.

GSK will initially employ about 200 staff and the company is investing in training and development to equip them with the skills and knowledge to operate the new facility.

In addition, as part of an ongoing effort to develop talent and leadership in Singapore, GSK is setting up a $30 million endowment fund here to nurture minds in the fields of green manufacturing and public health policy. The Singapore Economic Development Board (EBD) will boost the fund by a further $20 million.

GSK has had a strong presence in Singapore for the last 50 years since 1959. Besides the local pharmaceutical and consumer healthcare operations, Singapore serves as the headquarters for GSK's Asia-Pacific operations and houses the Singapore Research Centre at Biopolis. In addition to this new vaccine plant, GSK has two global manufacturing and supply sites located in Singapore. With more than 1000 staff, GSK's total investment in the city-state now exceeds S$1.5 billion.

Asia is emerging as a global powerhouse in the biomedical sciences industry, with its fast-expanding market and massive talent base. As a leading bio-cluster in Asia, Singapore provides access to world-class scientific and clinical excellence, excellent connectivity to key regional markets as well as strategic partnership opportunities with research institutes, corporate labs and public hospitals.

Leveraging Singapore's strong scientific and economic fundamentals, global biomedical sciences companies invested more than $500 million here in the year 2008 alone. A growing base of more than 50 global pharmaceutical, biotechnology and medical technology companies are carrying out R&D in Singapore, alongside 30 public-sector research and medical institutes. Amongst them, more than 10 leading multi-national companies have established their regional headquarters in Singapore. They include AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Merck, Quintiles and Sanofi-Aventis. Their continued confidence is testament to Singapore's position as a leading global manufacturing site for innovative medicines.

To find out more about working and living in Singapore, log on to Contact Singapore's website at or search for jobs at

For more information about Singapore's biomedical sciences sector, log on to the Singapore Economic Development Board's website at and the Agency for Science, Technology and Research's website at

About Contact Singapore

Contact Singapore is an alliance of the Singapore Economic Development Board and Ministry of Manpower. It aims to attract global talent to work, invest and live in Singapore.

With offices in Asia Pacific, Europe and North America, Contact Singapore is the one-stop center for those who wish to pursue a rewarding career in Singapore, as well as business leaders and entrepreneurs who are keen to invest in or initiate new business activities here. Contact Singapore actively links Singapore-based employers with global talent and provides updates on career opportunities and industry developments in Singapore. We work with private sector partners to facilitate the interests of potential individual investors in Singapore.

For more information on working, investing and living in Singapore, please visit


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands
2. GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus
3. Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009
4. GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
5. GlaxoSmithKline Update: Influenza A (H1N1)
6. GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
7. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
8. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
9. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
10. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
11. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
Post Your Comments:
Related Image:
GlaxoSmithKline Opens $600million Vaccine Plant In Singapore
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: